GB 12
Alternative Names: GB-12; GB12-09Latest Information Update: 07 Feb 2025
At a glance
- Originator Kexing Biopharm
- Class Anti-inflammatories; Bispecific antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 31 receptor antagonists; Interleukin 4 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis